ALK F1174V mutation confers sensitivity while ALK 11171 mutation confers resistance to alectinib. The importance of serial biopsy post progression

作者：Ou Sai Hong^*; Milliken Jeffrey C; Azada Michele C; Miller Vincent A; Ali Siraj M; Klempner Samuel J

来源：Lung Cancer, 2016, 91: 70-72.

DOI：10.1016/j.lungcan.2015.09.006

• Alectinib
• ALK inhibitor
• ALK-positive lung cancer
• ALK F1174V mutation
• ALK I1171S mutation
• Acquired resistance
• Comprehensive genomic profiling

Many acquired resistant mutations to the anaplastic lymphoma kinase (ALK) gene have been identified during treatment of ALK-rearranged non-small cell lung cancer (NSCLC) patients with crizotinib, ceritinib, and alectinib. These various acquired resistant ALK mutations confer differential sensitivities to various ALK inhibitors and may provide guidance on how to sequence the use of many of the second generation ALK inhibitors. We described a patient who developed an acquired ALK F1174V resistant mutation on progression from crizotinib that responded to alectinib for 18 months but then developed an acquired ALK I1171S mutation to alectinib. Both tumor samples had essentially the same genomic profile by comprehensive genomic profiling otherwise. This is the first patient report that demonstrates ALK F1174V mutation is sensitive to alectinib and further confirms missense acquired ALK 11171 mutation is resistant to alectinib. Sequential tumor re-biopsy for comprehensive genomic profiling (CGP) is important to appreciate the selective pressure during treatment with various ALK inhibitors underpinning the evolution of the disease course of ALK NSCLC patients while on treatment with the various ALK inhibitors. This approach will likely help inform the optimal sequencing strategy as more ALK inhibitors become available. This case report also validates the importance of developing structurally distinct ALK inhibitors for clinical use to overcome non-cross resistant ALK mutations.

• 出版日期2016-1